GU Cancers 2020 | EV-101: enfortumab vedotin for UC
Thanks for your feedback, this will help us improve our content for you!
Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, discusses results from the recent EV-101 study (NCT02091999), assessing the use of enfortumab vedotin in patients with metastatic urothelial carcinoma (UC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.
Get great new content delivered to your inboxSign up